Trial reportThe American journal of cardiology2022
Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction.
Trial report in The American journal of cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Therapeutic targeting of mitochondrial dysfunction in heart failure: a systematic review & meta-analysis of clinical outcomes.Frontiers in cardiovascular medicine · 2026Pooled it
- Dietary strategies and nutritional supplements in the management of heart failure: a systematic review.Frontiers in nutrition · 2024Pooled it
- Cardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.Journal of cardiovascular development and disease · 2026Review
- The Potential Role of Iron Homeostasis and Ferroptosis in Exercise Nutrition and Health.Nutrients · 2026Review
- Purine Nucleotide Precursors in Preventing Myocardial Ischemia-Reperfusion Injury.International journal of molecular sciences · 2025Review
- Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities.Heart failure reviews · 2025Review
- Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects.Bone research · 2025Review
- Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives.Frontiers in molecular biosciences · 2025Review
- Dietary Interventions in Heart Failure With Preserved Ejection Fraction: A Scoping Review.JACC. Advances · 2025Review
- The Role of Programmed Types of Cell Death in Pathogenesis of Heart Failure with Preserved Ejection Fraction.International journal of molecular sciences · 2024Review
- Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment.Reviews in cardiovascular medicine · 2024Review
- Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure.Journal of cardiovascular translational research · 2024Review
- Shenfu injection improves isoproterenol-induced heart failure in rats by modulating co-metabolism and regulating the trimethylamine-N-oxide - inflammation axis.Frontiers in pharmacology · 2024Article
- Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality.Current cardiology reports · 2023Review
- Dietary ribose supplementation improves flesh quality through purine metabolism in gibel carp (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with heart failure with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and it is not known if supplementing with ubiquinol and/or d-ribose could improve outcomes. The overall objective of this study was to determine if ubiquinol and/or d-ribose would reduce the symptoms and improve cardiac performance in patients with HFpEF. This was a phase 2 randomized, double-blind, placebo-controlled trial of 216 patients with HFpEF who were ≥ 50 years old with a left ventricular ejection fraction (EF) ≥ 50%. A total of 4 study groups received various supplements over 12 weeks: Group 1 received placebo ubiquinol capsules and d-ribose powder, Group 2 received ubiquinol capsules (600 mg/d) and placebo d-ribose powder, Group 3 received placebo ubiquinol capsules with d-ribose powder (15 g/d), and Group 4 received ubiquinol capsules and d-ribose powder. There were 7 outcome measures for this study: Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, level of vigor using a subscale from the Profile of Mood States, EF, the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (septal E/e' ratio), B-type natriuretic peptides, lactate/adenosine triphosphate ratio, and the 6-minute walk test. Treatment with ubiquinol and/or d-ribose significantly improved the KCCQ clinical summary score (17.30 to 25.82 points), vigor score (7.65 to 8.15 points), and EF (7.08% to 8.03%) and reduced B-type natriuretic peptides (-72.02 to -47.51) and lactate/adenosine triphosphate ratio (-4.32 to -3.35 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.